Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT04111172 |
TitleA Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase
Phase 2
|
Date Added 2019-10-01 |
Location
Pennsylvania, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03566355 |
TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer | Phase
Not Applicable
|
Date Added 2018-06-25 |
Location
Korea, Republic of
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Phase
Phase 1
|
Date Added 2019-12-04 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Korea, Republic of Netherlands Spain Taiwan United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03740256 |
TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Phase
Phase 1
|
Date Added 2018-11-14 |
Location
Texas, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
CAdVEC |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02453620 |
TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | Phase
Phase 1
|
Date Added 2015-05-25 |
Location
California, United States
Connecticut, United States Maryland, United States Pennsylvania, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy |
Tags
MSS/ MMRp
|
NCT ID NCT03170960 |
TitleStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2017-05-31 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium France Germany Italy Netherlands Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, Cabozantinib |
Tags
MSS/ MMRp
|
NCT ID NCT03600883 |
TitleA Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | Phase
Phase 1, Phase 2
|
Date Added 2018-07-26 |
Location
California, United States
Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Brazil Canada France Germany Greece Hungary Japan Korea, Republic of Portugal Romania Spain Switzerland |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Anti PD-1/L1, Midazolam, Sotorasib |
Tags
MSS/ MMRp
|
NCT ID PG545 (pixatimod) in combination with nivolumab |
TitlePG545 (pixatimod) in combination with nivolumab | Phase
Phase 1
|
Date Added 2019-04-26 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02668770 |
TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | Phase
Phase 1
|
Date Added 2016-01-29 |
Location
Texas, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Ipilimumab, MGN1703 |
Tags
MSS/ MMRp
|
NCT ID NCT02285816 |
TitleMG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours | Phase
Phase 1, Phase 2
|
Date Added 2014-11-07 |
Location
Canada
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
AdMA3, MG1MA3 |
Tags
MSS/ MMRp
|